A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study.

Lavinia Tan,Ben Tran,Jeanne Tie,Ben Markman, Sumi Ananda,Niall C Tebbutt,Michael Michael,Emma Link,Stephen Q Wong, Sushma Chandrashekar,Jerick Guinto,David Ritchie,Rachel Koldej,Benjamin J Solomon,Grant A McArthur,Rodney J Hicks,Peter Gibbs,Sarah-Jane Dawson,Jayesh Desai

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 5|浏览29

暂无评分

摘要

The Erlotinib and Vemurafenib In Combination Trial study demonstrated a safe and novel combination of two oral inhibitors targeting BRAF and EGFR. The dynamic assessment of serial ctDNA was a useful measure of underlying genomic changes in response to this combination and in understanding potential mechanisms of resistance.

查看译文

关键词

egfr inhibition,colorectal cancer,positive metastatic colorectal cancer,other cancers

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要